Partners Group Holding AG

Appendix to Our Report on Partners Group Holding AG

Appendix

Zenith Longitude Limited (Hong Kong company registry documents)

2025 annual return

 

2024 annual return

PG Investment Company 18 S.à.r.l

Bock Capital JVCo Nature S.à.r.l (Unit4, SaaS & Enterprise Software)

Root JVCo S.a r.l.

Ciddan S.à.r.l

Chain of Ownership Nizhpharm

Source: Nidda Lynx S.a r.l.’s 2025 annual report

The Chain Of Ownership

Master Fund → Ciddan S.à r.l. → Nidda Topco → Nidda Midco → Nidda Lynx → JSC Nizhpharm.

Partners Group Private Equity (Master Fund), LLC — the firm’s flagship US-investor vehicle — holds the Russian exposure through a Luxembourg chain that is forensically traceable in public filings.

The Master Fund acquired Ciddan S.à r.l. in September 2017, reporting two tranches: preferred equity at a cost of $27.82 million and common equity at a cost of $14.67 million.

Ciddan’s 2024 annual accounts, filed with the Luxembourg Registre de Commerce et des Sociétés, show that as of December 31, 2024, Ciddan owned:

49.78% of Nidda Topco S.à r.l.

50% of Nidda Manco GP GmbH

17.9% of Nidda Beteiligungs GmbH & Co KG

Nidda Topco’s 2024 accounts show 99.51% ownership of Nidda Midco S.à r.l. Nidda Midco’s accounts, in turn, disclose 100% ownership of four entities, including Nidda German Topco GmbH, Nidda Lynx S.à r.l., Stada Arzneimittel B.V., and Nidda Finco S.à r.l.

Nidda Lynx’s 2024 annual accounts, filed before the April 2025 decree, stated 100% ownership of JSC Nizhny Novgorod Chemical-Pharmaceutical Plant (JSC Nizhpharm), one of the largest domestic pharmaceutical manufacturers in Russia.

Ciddan’s 49.78% stake in Nidda Topco is a minority interest, not a control position. The STADA/Nidda group’s principal operating asset is the German pharmaceutical business Stada Arzneimittel AG; Nizhpharm was the group’s Russian operation. But Nidda Topco’s consolidated accounts include the subsidiaries below it in the chain (Nidda Midco at 99.51%, and Nidda Lynx at 100% of Nidda Midco), and Ciddan’s Master Fund position is carried at fair value reflecting its proportionate share of Nidda Topco’s consolidated net assets. The state transfer of Nizhpharm is therefore a direct impairment event to Nidda Topco’s consolidated net assets, and through Ciddan’s 49.78% stake, a proportionate impairment to the Master Fund’s underlying exposure.

The Ciddan markup Partners Group recorded during this exact reporting window would require the Valuation Designee to assume either (a) that the state transfer is temporary and reversible, (b) that Nizhpharm’s contribution to Nidda Topco’s consolidated value was immaterial, or (c) that some offsetting positive development at Nidda Topco or its other subsidiaries justified an overall 12% markup despite the Nizhpharm loss. None of those assumptions has been publicly disclosed. None is obviously supportable from the public record.

Orbiter Investments S.à r.l (Breitling, Luxury Watch Company)

Pharmathen Topco S.à.r.l